Possible Drug Interaction between Warfarin and Combination of Levamisole and Fluorouracil

1994 ◽  
Vol 28 (4) ◽  
pp. 464-467 ◽  
Author(s):  
Mary A. Scarfe ◽  
Marc K. Israel

OBJECTIVE: To report a possible drug interaction between the combination of fluorouracil (5-FU), levamisole, and warfarin. CASE SUMMARY: An elderly patient with chronic atrial fibrillation and prosthetic valve replacements had been taking warfarin 22.5 mg/wk. Following the diagnosis of colon cancer (Duke's classification D), a chemotherapy regimen of 5-FU and levamisole was started. Within four weeks after initiation of chemotherapy, the International Normalization Ratio (INR) increased from 3.04 to 39.56. Warfarin was discontinued and restarted at 7.5 mg/wk. Discontinuation of levamisole and 5-FU for a five-week period resulted in the INR falling to a subtherapeutic level. Reinstitution of the chemotherapeutic regimen once again led to an increase in INR. DISCUSSION: A literature search showed no reports of an interaction between warfarin and levamisole. However, prolongation of 5-FU half-life and an increase in INR have been reported with the concurrent use of 5-FU and warfarin. Inhibition of the hepatic metabolism of warfarin by 5-FU and levamisole is the postulated mechanism of this drug interaction. CONCLUSIONS: This case describes the clinically significant increase of INR in an elderly patient after adding a chemotherapy regimen of levamisole and 5-FU to a previous regimen of warfarin alone. The increasing incidence of both atrial fibrillation and colon cancer with age could potentially require the concomitant use of 5-FU, levamisole, and warfarin. Because of the potential severity of this interaction, close monitoring of INR and warfarin dosage adjustment is recommended in patients receiving warfarin along with levamisole and 5-FU.

2005 ◽  
Vol 19 (2) ◽  
pp. 123-124 ◽  
Author(s):  
Robert J. Anderson ◽  
Christine Divers ◽  
Irene von Hennigs

2018 ◽  
Vol 3 (1) ◽  

Mr. LPH, an 86 year old patient taking warfarin for atrial fibrillation (AF) is admitted for a vertebral fracture. His calculated CHADSs score was of 6. A suboptimal control of diabetes was detected. Metformin and glyburide were increased. Four days after discharge, Mr. LPH was readmitted due to diarrhea and hyperglycemia. Metformin was discontinued. Glyburide dose was adjusted. INR dosage results fluctuated during hospital stay over and under therapeutic values. Warfarin was discontinued and apixaban 2.5 mg twice daily was started. Mr. LPH was later admitted for a pulmonary severe sepsis. His infection was complicated by two AF episodes. After the last episode, Mr. LPH presented dysarthria, facial asymmetry and left hemiparesis. On the cerebral scan, we observed a right Sylvian artery stroke. Conclusion: In this case, the 2.5 mg apixaban dose was used and may explain the stroke. It occurred after two consecutive AF episodes making it the most likely cause. The choice of the low drug dosage may have been in response to caution and patient frailty. The patient was stable on warfarin for the past 14 years and the fluctuating INR episode can be explained by drug interaction. Glyburide may enhance the anticoagulation effect of warfarin.


2022 ◽  
Vol 4 (1) ◽  
Author(s):  
Tyan F. Thomas ◽  
Evdokia S. Metaxas ◽  
Thu Nguyen ◽  
Whitni Bennett ◽  
Kathryn V. Skiendzielewski ◽  
...  

Abstract Aim A case of an 85-year-old patient with concurrent use of warfarin and medical cannabis containing delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) is described. Warfarin continues to be a cornerstone of anticoagulation treatment despite the recent addition of FDA-approved anticoagulant agents. It is well known that warfarin has numerous drug interactions; however, much remains unknown about its interaction with THC and CBD. A literature review was conducted to identify documented cases of possible interactions between cannabis and warfarin. The case reports we identified noted that cannabis may potentially increase warfarin’s effect. Therefore, we aimed to determine why an effect was not seen on our patient’s warfarin dose despite daily use of medical cannabis. Case This case report describes an 85-year-old patient who despite starting an oromucosal medical cannabis regimen of THC and CBD (which provided 0.3 mg of THC and 5.3 mg CBD once daily and an additional 0.625 mg of THC and 0.625 mg CBD once daily as needed) had minimal INR fluctuations from October 2018 to September 2019. Conclusion Despite the introduction and use of medical cannabis therapy, with both THC and CBD components, an elderly patient with concurrent warfarin use did not see major INR fluctuations, in contrast to published literature. The potential for warfarin and THC/CBD interactions may be dependent on route of administration and dose of the cannabis product.


Sign in / Sign up

Export Citation Format

Share Document